Strategy, Aspermont, Redcare Pharmacy – Turnaround Opportunities Back in Focus

Strategy – A Risky Billion-Dollar Bet

The crypto market is catching its breath, at least in the short term. Recently, Bitcoin was able to briefly break through the psychologically important USD 70,000 mark again. Driven by sustained ETF inflows absorbing the tight supply and hopes for geopolitical détente, the world's largest cryptocurrency appears to be finding a stable footing. Michael Saylor, the driving force behind Strategy's aggressive crypto tactics, believes the market hit bottom back in February at around USD 60,000 and that the bears' selling pressure has now completely run out.

In line with this extremely bullish stance, Strategy is stepping on the gas. Completely unfazed by a massive paper loss of over USD 14 billion in the first quarter—which, at least on the balance sheet, is cushioned by lucrative tax benefits—the software company went on another major buying spree in early April. For just under USD 330 million, nearly 5,000 more coins found their way into the company's wallets.
The financing strategy chosen here is clever. Instead of tapping into existing assets, the company very successfully issued new preferred shares. Saylor brushes aside theoretical risks, such as the threat posed by quantum computers, as wildly exaggerated.

Rather, he is visionarily transforming the company into a vehicle for future crypto-based credit markets. This unshakable conviction is increasingly fueling investors' hopes for a sustainable turnaround of the recently battered stock, which immediately reacted to the latest buy transactions with noticeable price gains.

Wall Street analysts are also applauding this consistent strategy. Research firms such as Mizuho, Texas Capital, and B. Riley are confirming their "Buy" recommendations one after another. Mizuho continues to set an ambitious price target of USD 320 and praises the massive financial leeway for upcoming investments. Only crypto veterans like Willy Woo are still urging caution. After all, a definitive, market-wide buy signal will only emerge once investors' current wait-and-see attitude evolves into genuine buying interest.

Aspermont – Data Gold in the Commodities Boom

Analysts at GBC AG see a price potential of over 180% to a target price of EUR 3.03 for Aspermont. The company has undergone a fundamental transformation in recent years and now presents itself as a modern, subscription-driven provider of data, analytics, and intelligence solutions in the global commodities sector. What began as a long-established specialist publisher founded in 1835 has evolved into a specialized B2B data provider that reaches decision-makers in mining companies, among investors, and within governments. The focus on recurring subscription revenue ensures significantly improved revenue predictability, greater visibility, and growing pricing power.

With the Mining IQ platform, Aspermont is now taking the decisive step toward data-driven decision support, thereby tapping into significantly higher-margin revenue streams. Initial Tier-1 customers are already confirming the potential of this approach, as proprietary data sets and extensive archive content can be elevated to a new level of monetization.

The underlying platform model is capital-light and highly scalable, allowing additional revenue to be generated at comparatively low incremental costs, which is expected to lead to significant operational leverage in the medium term. A clear growth trajectory is therefore anticipated for the coming years. Revenue is projected to rise from AUD 16.90 million in 2026 to AUD 21.30 million in 2028. In parallel, EBITDA is expected to improve from AUD 0.15 million in 2026 to AUD 2.93 million in 2028, while net income is projected to turn profitable as early as 2027 at AUD 0.53 million, following a loss of AUD 0.95 million in 2026.

This development is driven in particular by rising average revenue per customer, more intensive use of the platform among existing corporate clients, and cross-selling between subscriptions, data products, events, and marketing services. At the same time, the solid balance sheet with improved liquidity and low debt provides sufficient leeway to drive further growth without short-term financing pressure. Overall, Aspermont combines an established network, high-quality data assets, and a clearly scalable business model that meets rising demand in an increasingly data-driven commodities sector and has the potential to establish itself as a hidden champion in the B2B data intelligence space.

Redcare Pharmacy - A Breakthrough After a Long Downturn

The mail-order pharmacy has recently faced an extremely difficult situation in the capital market. Shareholders have had to cope with significant price losses since the beginning of the year, as the MDax-listed company lacked real profits despite steady expansion. While the online retailer is benefiting from the ongoing decline of local pharmacies, competitive pressure is simultaneously growing from established drugstore chains that are increasingly pushing into the digital healthcare sector. Consequently, the stock had long been among the weakest performers on the local market.

Now, the preliminary quarterly figures have provided a strong boost. Consolidated revenue rose by 18.3% year-over-year to EUR 848 million. The main driver of this positive development was the prescription drug segment, which grew by more than a third. Sales of over-the-counter products, which generate higher margins, also rebounded more strongly. At the same time, the company significantly expanded its reach and now serves over 14 million active buyers.

Management sees the company as being on track and reaffirmed its previous annual forecasts. The results sparked euphoria on the trading floor, as share prices shot up by double digits at times. From a technical analysis perspective, indicators had previously pointed to a massively oversold situation. This attracted contrarian investors and fueled a dynamic rebound, possibly supported by covering by short sellers. Nevertheless, chart analysts urge caution, as the overarching downward trend has not yet been definitively broken.

A consistent crypto strategy and institutional inflows are driving turnaround expectations at Strategy. Aspermont stands out with a scalable data model, rising margins, and over 180% upside potential. Redcare Pharmacy impresses with strong revenue growth, a growing customer base, and initial rebound momentum.